Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy | Zendy

Matthew J. Akiyama | Zendy; Daniel Lipsey | Zendy; Moonseong Heo | Zendy; Linda Agyemang | Zendy; Brianna L. Norton | Zendy; Jennifer Hidalgo | Zendy; Kiara Lora | Zendy; Alain H. Litwin | Zendy

Open Access

Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy

Author(s) -

Matthew J. Akiyama,

Daniel Lipsey,

Moonseong Heo,

Linda Agyemang,

Brianna L. Norton,

Jennifer Hidalgo,

Kiara Lora,

Alain H. Litwin

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz693

Subject(s) - medicine , viremia , hepatitis c , incidence (geometry) , hepatitis c virus , combination therapy , immunology , virus , physics , optics

Direct-acting antiviral (DAA) therapy is highly effective in people who inject drugs (PWID); however, rates, specific injection behaviors, and social determinants associated with hepatitis C virus (HCV) reinfection following DAA therapy among PWID on opioid agonist therapy (OAT) are poorly understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research